In Brief: Isolyser/Microtek
This article was originally published in The Gray Sheet
Executive Summary
Isolyser/Microtek: Revise previously announced merger agreement due to the "recent trading prices of Isolyser common stock below $13 per share which, under the previous merger agreement, would have netted Microtek's shareholders substantially less than" the agreed on price of $16.50 per share, the companies say. Isolyser, developer of the Orex Degradables technology, and Microtek, a manufacturer of disposable drapes and fluid control pouches, announced plans to merge in March ("The Gray Sheet" March 25, I&W-9). Under revised terms of the deal, Microtek shareholders will receive $16.50 of Isolyser stock if the average price of Isolyser shares is between $10 and $15 per share. Microtek shareholders will receive one share of Isolyser stock for each Microtek share if Isolyser stock trades above $15; they will receive 1.65 shares of Isolyser stock if Isolyser trades for $10 or below. Both firms retain an option to terminate the deal if Isolyser shares dip below $10...
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.